|
||||||||||||||||||
|
|
||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionIFN-λs are a novel family of interferons which mediate the induction of anti-viral protection in a wide variety of cells. The three members of the IFN-λ family are λ1, λ2, and λ3, also known as IL-29, IL-28A, and IL-28B, respectively. IFN-λs share with type I IFNs an intracellular signaling pathway that drives the expression of a common set of IFN-stimulated genes. IFN-lambdas induce multiple biological activities, including the upregulation of class I MHC gene product expression to levels comparable to those induced by IFN-αs. IL-28 and IL-29 are tested for anti-viral activity by challenging the human hepatocellular carcinoma cell line HepG2 with infection by EMC (following pretreatment of the cells with cytokine). Consistent with a role in anti-viral protection, the mRNA expression of IFN-lambdas is detectable in cells infected with various viruses. Moreover, monocyte-derived dendritic cells (important producers of IFN-α) express IFN-λ1 mRNA in response to treatment with dsRNA. TLR3 and TLR4 ligands induce IFN-α, IFN-β, IL-28, and IL-29 gene expression in macrophages; this is dependent upon IFN-α. IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex distinct from that of type I IFNs. This is comprised of two essential receptor proteins, CRF2-12/IFN-λR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. Whereas, the two chains of the type I IFN receptor (IFN-AR1 and IFN-AR2) and IL-10R2 are ubiquitously expressed, IFN-λR1 expression is limited and cell-type dependent. IFN-λR1 is not expressed by monocytes, but is up-regulated during GM-CSF/IL-4 induced differentiation of DCs from human monocytes, yielding iDCs which are fully responsive to IFN-λ. The IFN-λs, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. IFN-λ-matured DCs express high levels of class I and II MHC gene products, but low levels of costimulatory molecules, and are able to specifically induce IL-2-dependent proliferation of CD4+CD25+FOXP3+ T cell population with contact dependent suppressive activity on T cells. Applications ReportedFor research use only, not for diagnostic or therapeutic use. The recombinant mouse IL-28 is fully biologically active and has been reported for use in bioassay. Applications TestedThe recombinant mouse IL-28 has been tested for inhibition of the cytopathic effect of EMC virus on HepG2 cells. The ED50 for this effect is typically below 50.0 ng/ml, corresponding to a specific activity of >2.0 x 10E4 U/mg. References
Kotenko, S., et al. 2003. IFN-lambdas mediate anti-viral protection through a distinct class II cytokine receptor complex. Nature Immunol. 4: 69-77. Mennechet, F., et al. 2006. IFN-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Immunobiology. 107: 4417-4423. Sheppard, P., et al. 2003. IL-28, IL-29, and their class II cytokine receptor IL-28R. Nature Immunol. 4: 63-68. |
||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |